Brain Scientific Featured in Syndicated Broadcast Covering Receipt of FDA Clearance for Next-Gen NeuroCap EEG Headset
Brain Scientific (OTCQB: BRSF) announced its feature in an audio broadcast via NetworkNewsAudio, boosting visibility and brand awareness in the investment community. The release highlights the FDA 510(k) clearance for its NeuroCap™, an advanced EEG electrode array designed for quick EEG recordings in clinical settings. The NeuroCap™ has been improved with better adhesion and a new extra small size, increasing its application scope. This disposable EEG headset is compatible with most encephalographs and can be applied in just five minutes.
- FDA 510(k) clearance for NeuroCap™, enhancing marketability.
- Improvements in NeuroCap™ design with better adhesion and new size options.
- Rapid application time (five minutes) for better clinical efficiency.
- None.
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF ) today announces it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers Brain Scientific’s receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired.
To hear the audio production, visit: https://nnw.fm/um28X
To read the original press release, visit: https://nnw.fm/TgVmq
“We are constantly working on new products for the EEG market. In the new version of NeuroCap™, we added velcro strips for better adhesion. We also expanded the size range by adding an XS (extra small) size. And now this device is designed for broader use – in addition to intensive care units and ERs,” said Irina Nazarova, marketing director at Brain Scientific.
NeuroCap™ is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels located in accordance with the 10-20 system. Pre-gelled, fixed electrode locations eliminate time-consuming tasks of head measurement and electrode placement. The cap is FDA-cleared to stay on a patient’s head for up to four hours. NeuroCap™ is compatible with most encephalographs on the market and can be applied in just five minutes.
About Brain Scientific
Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The Company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions and bridge the widening gap in access to neurological care.
For more information, visit the company’s website at www.brainscientific.com.
About NetworkNewsAudio
NetworkNewsAudio (“NNA”), one of 50+ brands within the InvestorBrandNetwork (“IBN”), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to several risks and uncertainties and other influences, over many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the recent FDA approval related to Brain Scientific (BRSF)?
What are the new features of the NeuroCap™ device from Brain Scientific (BRSF)?
How quickly can the NeuroCap™ from Brain Scientific (BRSF) be applied?
How many electrodes does the NeuroCap™ device have?
Where can the NeuroCap™ be used according to Brain Scientific (BRSF)?
